Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...
Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
Australia’s regulatory agency rejected Biogen and Eisai’s Alzheimer’s drug Leqembi, noting that the drug's efficacy doesn't ...
In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
“We might be able to have a big impact.” Since January 2023, two new drug treatments — Leqembi made by Eisai and Biogen and Kisunla made by Eli Lilly — have been approved by the Food and ...
About 6% of Leqembi is thrown away because there’s leftover drug after a dose is drawn to match a person’s weight Adding a 75-milligram vial could reduce waste by 74% and save Medicare as much ...
A much-anticipated drug that holds the promise of delaying symptoms of Alzheimer’s disease will not be available in Australia ...
Half of people who develop blood poisoning, otherwise known as sepsis, are dead within a couple of years, a new study finds.